Practitioner's Docket No. 00228-US-NEW2C1 *PATENT*

OIPE JC179 APR 0 9 2001 PATENT & TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
ANDERSON, John P. et al.	Examiner: Unknown
Application No.: 09/723,722	Group No.: 1642
Filed: 11/28/2000	
For: BETA-SECRETASE ENZYME COMPOSITIONS AND METHODS	

Certificate of Mailing (37 C.F.R. § 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Box Missing Parts, Assistant Commissioner for Patents, Washington, D.C., 20231.

Date: 4/5/01 By: Franklin Gr

BOX MISSING PARTS
Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

Dear Sir:

1. This replies to the Formalities Letter DATED **January 10, 2001**.

 A copy of the Office communication is enclosed.

2. Submitted herewith are:

 A. Statutory basic filing fee in the amount of $710.00.

 B. Additional claim fees in the amount of $3,758.00.

 - $1,998.00 for 111 total claims over 20
 - $1,760.00 for 22 independent claims over 3

C. Late filing fee surcharge as set forth in 37 CFR 1.16(e) in the amount of $130.00 for a non-small entity.

D. A preliminary amendment directing entry into the specification, and to the description and/or claims, wherein reference is made to the sequence by use of the assigned identifier, as required in 37 CFR 1.821(d).

E. A request to use the computer readable form (CRF) of the Sequence Listing filed in the parent case as permitted by 37 C.F.R. § 1.821(e) and 1.824 and matching hard copy of that sequence listing.

F. A statement that the content of each Sequence Listing submitted and each Computer readable copy are the same, as required in 37 C.F.R. § 1.821(g).

G. Return Postcard

3. Fee payment

Fee payment in the amount of $4,598.00 is being made at this time.

4. Method of fee payment

Charge Account No. 01-2707, in the amount of $4,598.00
A duplicate of this Cover Sheet is attached.
Please charge Account No. 01-2707 for any fee deficiency.

Respectfully submitted,



SIGNATURE OF PRACTITIONER

Date: 4/5/01

Nina M. Ashton

Reg. No. 37,273
Tel. No.: (650) 616-2639

Elan Pharmaceuticals, Inc.
800 Gateway Boulevard
South San Francisco, CA 94080

Customer No.: 21835

3

OIPE JC179
APR 0 9 2001
PATENT & TRADEMARK OFFICE

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/723,722	11/28/2000	John P. Anderson	00228-US-NEW2C1

21835
ELAN PHARMACEUTICALS, INC.
INTELLECTUAL PROPERTY DEPARTMENT
800 GATEWAY BOULEVARD
SOUTH SAN FRANCISCO, CA 94080

FORMALITIES LETTER

OC000000005668678

Date Mailed: 01/10/2001

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Filing Date Granted

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given TWO MONTHS from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The statutory basic filing fee is missing.
 Applicant must submit **$ 710** *to complete the basic filing fee and/or file a small entity statement claiming such status (37 CFR 1.27).*
- Total additional claim fee(s) for this application is $3758.
 - **$1998** for **111** total claims over 20.
 - **$1760** for **22** independent claims over 3 .
- To avoid abandonment, a late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of $130 for a non-small entity, must be submitted with the missing items identified in this letter.

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):
 - This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required under 37 CFR 1.821(e).

 For questions regarding compliance to these requirements, please contact:

 - For Rules Interpretation, call (703) 308-1123
 - For CRF Submission Help, call (703) 308-4212
 - PatentIn Software Program Support
 - - For Technical Assistance, call (703) 287-0200
 - - To Purchase PatentIn Software, call (703) 306-2600

04/11/2001 SDENBOB1 00000015 012707 09723722
01 FC:101 710.00 CH
02 FC:102 1760.00 CH
03 FC:103 1998.00 CH
04 FC:105 130.00 CH

- **The balance due by applicant is $ 4598.**

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center
Initial Patent Examination Division (703) 308-1202
PART 1 - ATTORNEY/APPLICANT COPY